Who is sponsoring NCT04177108?

NCT04177108 is sponsored by Hoffmann-La Roche.

What condition does NCT04177108 study?

NCT04177108 studies Triple-Negative Breast Cancer.

What drugs are being tested in NCT04177108?

Interventions: Atezolizumab, Ipatasertib, Paclitaxel, Placebo for Atezolizumab, Placebo for Ipatasertib.

What is the status of NCT04177108?

NCT04177108 is currently COMPLETED.

Last reviewed 2024-03-27 · How we verify

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04177108 PHASE3 COMPLETED Results posted

This study evaluated the efficacy and safety of ipatasertib in combination with atezolizumab and paclitaxel in locally advanced or metastatic Triple-Negative Breast Cancer (TNBC) previously untreated in this setting.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE3
Status	COMPLETED
Enrolment	242
Start date	Mon Nov 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Triple-Negative Breast Cancer

Interventions

Atezolizumab
Ipatasertib
Paclitaxel
Placebo for Atezolizumab
Placebo for Ipatasertib

Countries

Hong Kong, Colombia, Finland, Italy, Japan, Taiwan, Poland, South Korea, Denmark, New Zealand, Costa Rica, Russia, Belgium, Mexico, Thailand, Bulgaria, Czechia, Portugal, United States, France, South Africa, Greece, Austria, Israel, Argentina, Canada, Romania, Brazil, Spain, Ukraine